DOCSLIB.ORG

Dobutamine Versus Levosimendan for Patients with Acute Decompensated Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dobutamine Versus Levosimendan for Patients with Acute Decompensated Heart Failure www.medigraphic.org.mx Revista Mexicana de Cardiología Original Research Vol. 27 No. 1 January-March 2016 Dobutamine versus levosimendan for patients with acute decompensated heart failure Dobutamina versus levosimendán en pacientes con insuficiencia cardiaca agudizada Tomás Miranda-Aquino,* Silvia Esmeralda Pérez-Topete,* Ramón Javier Treviño-Frutos,** Manuel Nicolás Guerra-Villa* Key words: Heart failure ABSTRACT RESUMEN worsened, dobutamine, Introduction: Heart failure remains a highly frequent Introducción: La insuficiencia cardiaca agudizada levosimendan, LVEF. cause of hospitalization; with a high morbidity and mortal- continúa siendo una causa altamente frecuente de hospi- ity. Objectives: The aim of this study is to compare the talización con una gran morbimortalidad. Objetivos: El Palabras clave: 30-day in hospital survival of patients treated with Levosi- objetivo primario es comparar la sobrevida a 30 días de Insuficiencia mendan vs. Dobutamine in acute decompensated heart fail- los pacientes tratados con levosimendán versus dobuta- cardiaca agudizada, ure. Secondary aims will be to compare the measurement mina en insuficiencia cardiaca agudizada. Como objetivo dobutamina, of LVEF before and after inotropic and length of hospital secundario será comparar la determinación de la FEVI levosimendán, FEVI. stay. Material and methods: Observational, descriptive, pre- y post-inotrópico y días de estancia hospitalaria. retrospective study. All adult patients were admitted to the Material y métodos: Estudio observacional, descriptivo, Hospital Christus Muguerza Alta Especialidad, with acute retrospectivo. Se recabaron todos los pacientes adultos que decompensated heart failure diagnosis and have required hayan ingresado en el Hospital Christus Muguerza Alta inotropic support in the period January 2013 to September Especialidad, con diagnóstico de insuficiencia cardiaca 2015 were collected. Results: 83 patients were included, agudizada y que hayan requerido el apoyo de inotrópicos, however only 38 met the inclusion criteria. Of the en el periodo comprendido de enero de 2013 a septiembre 38 patients 20 (53%) were prescribed levosimendan de 2015. Resultados: Se documentaron 83 pacientes con and 18 (47%) dobutamine. The average age in both diagnóstico de insuficiencia cardiaca agudizada, de los groups was 62.2 years (± 15.6) of levosimendan versus cuales sólo 38 cumplieron con los criterios de inclusión. De dobutamine 78.8 years (± 10.6) (p = 0.0005). Survival los 38 pacientes a 20 (53%) se les indicó levosimendán y a at 30 days was 100% in levosimendan versus 77.8% 18 (47%) dobutamina. La media de edad en ambos grupos in dobutamine (p = 0.0274). In days of hospital stay it fue de 62.2 años (±15.6) de levosimendán versus 78.8 años was 9.3 days (± 5.1) levosimendan and 13.8 days (± 6.5) de dobutamina (±10.6) (p = 0.0005). La supervivencia a 30 in dobutamine (p = 0.02). postinotropic LVEF change was días fue de 77.8% en dobutamina versus 100% levosimen- 18.3% (± 6.2) levosimendan versus 18.7% (± 9.9) dobu- dán (p = 0.0274). En días de estancia hospitalaria fue de tamine (p = 0.88). Conclusions: The use of dobutamine 9.3 días (± 5.1) en levosimendán y de 13.8 días (± 6.5) en leads to a lower survival to 30 days, in addition to longer dobutamina (p = 0.02). El cambio FEVI postinotrópico fue hospital stay. However no difference in LVEF values at de 18.3% (± 6.2) levosimendán versus 18.7% (± 9.9) dobu- * Hospital Christus admission or inotropic post. tamina (p = 0.88). Conclusiones: El uso de Dobutamina Muguerza Alta Especialidad/ conlleva a una menor sobrevida a 30 días, además de tener Universidad de mayor estancia hospitalaria. Sin embargo no hay diferencia Monterrey. en los valores de FEVI al ingreso ni postinotrópico. ** Departamento de Educación e www.medigraphic.org.mx Investigación de Salud Christus Muguerza. Recibido: 16/12/2015 Aceptado: 18/02/2016 Rev Mex Cardiol 2016; 27 (1): 44-49 www.medigraphic.com/revmexcardiol Miranda-Aquino T, et al. Dobutamine versus levosimendan for patients with acute decompensated heart failure 45 INTRODUCTION levosimendan versus dobutamine in acute de- compensated heart failure. Secondary aims will he term acute heart failure includes a group be to compare the measurement of LVEF before of related clinical syndromes, defined as T and after inotropic and length of hospital stay. a gradual or rapid change in the signs and symptoms of heart failure, resulting in a need MatERIAL AND METHODS for urgent therapy. It is a critical inability of the myocardium to maintain an adequate cardiac Observational, descriptive, retrospective study. output to meet the demands of the peripheral Study Data was collected from the records of circulation. Acute Heart failure can present as the department of statistics. Were selected all new onset or worsening of preexisting chronic patients who entered with the diagnosis of heart failure.1 acute decompensated heart failure during the It is the leading cause of hospitalization in period from January 2013 to September 2015 patients over 65 years, the rate of hospitaliza- at Christus Muguerza High Specialty Hospital. tion is increasing due to the progressive aging All information was collected from medical of the population and a better management of records and include all patients over 18 years acute myocardial infarction. Moreover, nearly with the diagnosis of acute decompensated 50% of patients hospitalized with acute heart heart failure who have required inotropic sup- failure are readmitted within 6 months after port and have had oliguria. Patients with per- discharge. Hospital mortality is about 5% and sistent systolic BP < 85 mmHg, persistent heart the risk of death or rehospitalization within 2-3 rate > 130 bpm and a history of arrhythmias months ranges from 20% to 60% depending on were excluded. the population study.1 The Excel program and Medcalc program In theory, inotropic agents improve hemo- was used. To compare survival, the Kaplan-Mei- dynamic parameters, increasing cardiac output er curve was used. Comparison of Means Using and reducing the filling pressure of the left and Student’s t-Test and chi-square calculations to the right ventricle by increasing myocardial compare proportions. Medical records were contractility. Consequently, they are indicated used to look for 30 days survival, comorbidi- for treating both patients with peripheral hy- ties, base treatment, length of stay in hospital, poperfusion and water retention caused by age. For the calculation of LVEF aPhillips hd7 deterioration of cardiac contractility.2-4 echocardiogram was used and by a biplane Dobutamine is a synthetic catecholamine method the LVE was calculated, the result was acting primarily through stimulation of β1 obtained from medical records. receptors and partly through β2 receptors to As operational definitions: acute heart produce positive inotropic and chronotropic failure: patient who meets exacerbation of depending of the dose.5-7 dyspnea in addition to a LVEF of 50% found Levosimendan is a pyridazinone-dinitrile by transthoracic echocardiography. Oliguria: derivative acts by increasing the affinity of tro- patient presenting diuresis less than < 0.5 ponin C to calcium and stabilizes the conforma- mL/kg/hr. tion of troponin C. By improving the sensitivity The study followed the ethical guidelines of the contractile apparatus to intracellular in accordance with the ethical standards of the calcium, it has positive inotropic properties Helsinki Declaration of 1975 with last update in without impairing relaxation ventricular nor 2013 and the Scientific and Ethics Committee induce cytosolic calcium overload.8-12 of the institution where it was made. There are multiple studies in which the ef- www.medigraphic.org.mxNo external sources of finance were re- fectiveness of these two drugs are compared, quired. There are no conflicts of interest. but in Mexico there is no reported series.13-19 RESULTS OBJECTIVE The aim of this study is to compare the 30-day During the period from January 2013 to Sep- in hospital survival of patients treated with tember 2015, 83 patients diagnosed with acute Rev Mex Cardiol 2016; 27 (1): 44-49 www.medigraphic.com/revmexcardiol 46 Miranda-Aquino T, et al. Dobutamine versus levosimendan for patients with acute decompensated heart failure heart failure were selected, of which only 38 Table I. Baseline characteristics of the patients. met the inclusion criteria. A 37 % of them were males and 63% fe- General population n = 38 males. The average age was 70.1 years (±15.7). Among the most frequent comorbidities, Gender Male 14 (37%) diabetes mellitus (53%) and arterial hyperten- Female 24 (63%) sion (53%) were the most prevalent. About Age (years) 70.1 (± 15.7) base treatment of patients, it was evidenced Comorbilities DM 20 (53%) that beta-blockers (37%) and ACE inhibitors HTN 20 (53%) (37%) were the most prevalent. The rest of the AMI 10 (26%) characteristics of the study population can be AF 4 (11%) found in table I. Cardiomyopathy 2 (5%) In 20 patients of 38 (53%) were prescribed Malignancies 4 (11%) with levosimendan and 18 (47%) with dobu- CKD 6 (16%) tamine (Table II). The average of hospital stay Rheumatolology 4 (11%) was 11.5 days (± 6.2); of the total of patients Hypothyroidism 4 (11%) there were 4 (11%) who died. The average in- Baseline treatment BB 14 (37%) come of LVEF was 27% (± 10%), post-inotropic ARB 8 (21%) management was 46% (± 9.6), having a mean ACEi 14 (37%) change in LVEF of 18.5% (± 8%).The average CCB 2 (5%) of LVEF during income was 27% (± 10%), post- Diuretic 10 (26%) inotropic management was 46% (±9.6), having ARA 4 (11%) a mean change in LVEF of 18.5% (± 8%). Digoxin 4 (11%) By comparing levosimendan versus dobu- Nitrates 4 (11%) tamine groups (Table III), it was demonstrated Statins 6 (15%) that the proportion of female was 50 versus Antiplatelets 12 (32%) 78% (p = 0.15) respectively. The average age Insuline 8 (21%) in both groups was 62.2 years (± 15.6) of le- OA 8 (21%) vosimendan versus 78.8 years (± 10.6) (p = Others 8 (21%) 0.0005).
Load more

Recommended publications
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Simdax® Gives You Time in Acute Heart Failure
    SIMDAX ® GIVES YOU TIME IN ACUTE HEART FAILURE 1 SIMDAX® RELIEVES Improvement in clinical status Improved SYMPTOMS 20 p=0.015 19.4% 14.6% Levosimendan + SOC (n=299) IN AHF 10 Placebo + SOC (n=301) p=0.015 SIMDAX® improves symptoms of dyspnoea 0 and fatigue in acute heart failure. In the The primary endpoint result in the -10 REVIVE trial1, composite consisting Phase III regulatory study REVIVE, symptoms of patients’ subjective symptom -19.4% assessments (at 6 hours, 24 hours, over the 5-day assessment period improved -20 and 5 days) and signs of worsening -27.2% symptoms (including death) during significantly more with SIMDAX® than with Patients improved or worsened (%) the 5 days after starting drug -30 Worsened infusion. placebo when administered on top of the standard of care.1 Improvement in dyspnea 100 Generalized linear model p=0.018 Levosimendan + SOC (n=299) 90 Placebo + SOC (n=301) 80 Effects of levosimendan vs 70 placebo on top of standard of care on dyspnea in patients with AHF.4 60 Patients improved (%)* 6 hrs 24 hrs 48 hrs Day 3 Day 5 Reference: 1. Packer M. et al. JCHF. 2013;1(2): 103-11. *Includes mild, moderate and marked improvement on a 7-point scale 2 …WITH SUSTAINED HEMODYNAMIC AND Levosimendan + SOC (n=299) NEUROHORMONAL EFFECTS Placebo + SOC (n=301) The hemodynamic effects of SIMDAX® Sustained hemodynamic effects on cardiac output (CO) and pulmonary 1 CO (L/min) Max capillary wedge pressure (PCWP) have been End PCWP (mmHg) 0 1-3 24-hr infusion Figure 1: Duration of action of shown in several clinical trials.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: a Systematic Review and Meta-Analysis
    Journal of Clinical Medicine Review Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis 1, 2, 1 3 Mina Karami y , Veemal V. Hemradj y, Dagmar M. Ouweneel , Corstiaan A. den Uil , Jacqueline Limpens 4, Luuk C. Otterspoor 5, Alexander P. Vlaar 6 , Wim K. Lagrand 6 and José P. S. Henriques 1,* 1 Heart Center, Department of Interventional Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] (M.K.); [email protected] (D.M.O.) 2 Department of Cardiology, Isala, 8025 AB Zwolle, The Netherlands; [email protected] 3 Departments of Cardiology and Intensive Care Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; [email protected] 4 Medical Library, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] 5 Heart Center Catharina Hospital, 5623 EJ Eindhoven, The Netherlands; [email protected] 6 Department of Intensive Care, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] (A.P.V.); [email protected] (W.K.L.) * Correspondence: [email protected] These two authors contributed equally. y Received: 5 May 2020; Accepted: 25 June 2020; Published: 30 June 2020 Abstract: Vasopressors and inotropes are routinely used in acute myocardial infarction (AMI) related cardiogenic shock (CS) to improve hemodynamics. We aimed to investigate the effect of routinely used vasopressor and inotropes on mortality in AMI related CS. A systematic search of MEDLINE, EMBASE and CENTRAL was performed up to 20 February 2019.
    [Show full text]
  • Study Protocol
    Product: Omecamtiv Mecarbil (AMG 423) Protocol Number: 20110203 Date: 13 November 2018 Page 1 of 85 Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Amgen Protocol Number (Omecamtiv Mecarbil [AMG 423]) 20110203 EudraCT number 2016-002299-28 NCT Number NCT02929329 GALACTIC-HF Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure Clinical Study Sponsor: Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone: 1-805-447-1000 Key Sponsor Contact(s): One Amgen Center Drive Thousand Oaks, CA 91320-1799 Phone: Email: Date: 31 August 2016 Amendment 1 07 September 2017 Amendment 2 13 November 2018 Confidentiality Notice This document contains confidential information of Amgen Inc. Approved This document must not be disclosed to anyone other than the site study staff and members of the institutional review board/independent ethics committee/institutional scientific review board or equivalent. The information in this document cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Amgen Inc. If you have questions regarding how this document may be used or shared, call the Amgen Medical Information number: US sites, 1-800-77-AMGEN, Canadian sites, 1-866-50-AMGEN; all other countries call 1-800-772-6436. Amgen’s general number in the US (1-805-447-1000). CONFIDENTIAL Product: Omecamtiv Mecarbil (AMG 423) Protocol Number: 20110203 Date: 13 November 2018 Page 2 of 85 Investigator’s Agreement I have read the attached protocol entitled A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction, dated 13 November 2018, and agree to abide by all provisions set forth therein.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • The Calcium Sensitizer Levosimendan Improves Human Diaphragm Function
    Page 1 of 41 The calcium sensitizer levosimendan improves human diaphragm function Jonne Doorduin MSc 1, Christer A Sinderby PhD 5,7 , Jennifer Beck PhD 6,7 , Dick F Stegeman PhD 2,4 , Hieronymus WH van Hees PhD 3, Johannes G van der Hoeven MD 1, and Leo MA Heunks MD 1 1Department of Critical Care Medicine, 2Department of Neurology and 3Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, The Netherlands; 4Faculty of Human Movement Sciences, Research Institute MOVE, VU University, Amsterdam, The Netherlands; 5Department of Medicine, Division of Critical Care Medicine, 6Department of Pediatrics, St. Michael’s Hospital, University of Toronto, Canada; 7Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, University of Toronto, Canada. Address for correspondents and requests: Leo Heunks, MD, PhD Radboud University Nijmegen Medical Centre Department of Critical Care Medicine Geert Grooteplein zuid 10 6525 GA Nijmegen The Netherlands tel. : +31 24 36 17273 fax. : +31 24 35 41612 [email protected] Page 2 of 41 Author’s contributions Literature search: JD, LH; Study design: JD, CS, JB, DS, LH; Data collection: JD, LH; Data analysis: JD, LH; Data interpretation: JD, CS, JB, DS, HH, JH, LH; Writing: JD, CS, JB, DS, HH, JH, LH. Source of funding This study was investigator initiated and financed by institutional resources. This study was designed and conducted by the authors without involvement of Orion Pharma, or any other commercial party. Data analysis and writing the manuscript was performed by the authors without involvement of a commercial party. Levosimendan and placebo were an unrestricted gift from Orion Pharma (Espoo Finland).
    [Show full text]
  • Tecoland API Product List Sr No Name
    Tecoland API Product List Sr No Name 1 Meropenem 2 Vancomycin HCl 3 Dexrazoxane HCl 4 Levosimendan 5 Enfuvirtide 6 Clindamycin Phosphate 7 Vecuronium Bromide 8 Irinotecan HCl 9 Caspofungin 10 Methotrexate Sodium 11 Paclitaxel 12 Piperacillin + Tazobactam 13 Neomycin Sulfate 14 Ampicillin/sulbactam sodium 15 Atazanavir Sulfate 16 Cisatracurium Besylate 17 Docetaxel Anhydrous 18 Teicoplanin 19 Dexmedetomidine HCl 20 L-Carnitine Base 21 Rocuronium Bromide 22 Efinaconazole 23 Lamivudine 24 Amifostine 25 Cisplatin 26 Enoxaparin Sodium 27 Dexmedetomidine Base 28 Cephradine 29 Ampicillin sodium Tecoland API Product List Sr No Name 30 Sodium Nitroprusside 31 Ertapenem sodium 32 Loratadine 33 Docetaxel Trihydrate 34 Mitoxantrone Hcl 35 Linezolid 36 Esmolol HCl 37 Cefotaxime sodium 38 Bosentan monohydrate 39 Ezetimibe 40 Sevoflurane 41 Hydrocortisone base 42 Leflunomide 43 Fludarabine phosphate 44 Moxifloxacin HCl 45 Montelukast Sodium 46 Amphotericin B 47 Palonosetron Hcl 48 Ifosfamide 49 Ceftazidime 50 Nitrofurantoin 51 Lincomycin HCl 52 Cephapirin Benzathine 53 Lopinavir 54 Mesna 55 Erlotinib HCl 56 Granisetron HCl 57 Hyaluronate Sodium 58 Temozolomide Tecoland API Product List Sr No Name 59 Pyridoxine HCl 60 Suxamethonium Chloride 61 Tetracycline HCl 62 Hydralazine HCl 63 Glatiramer Acetate 64 Penciclovir 65 Cyclosporine 66 Irbesartan 67 Flumazenil 68 Calcium Folinate 69 Felodipine 70 Anidulafungin 71 cytarabine 72 Travoprost 73 Sugammadex Sodium 74 Oritavancin 75 Milrinone 76 Benzocaine 77 Simvastatin 78 Fosaprepitant dimeglumine 79 Oseltamivir
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update Horizon
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: July 2014 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 July 2014 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]
  • Levosimendan in Patients with Left Ventricular Dysfunction
    www.nature.com/scientificreports OPEN Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysis Received: 8 February 2018 Accepted: 8 May 2018 and trial sequential analysis of Published: xx xx xxxx randomized trials Zhenhua Xing , Liang Tang, Pengfei Chen, Jiabing Huang, Xiaofan peng & Xinqun Hu Patients with left ventricular dysfunction (LVD) undergoing cardiac surgery have a high mortality rate. Levosimendan, a calcium sensitizer, improves myocardial contractility without increasing myocardial oxygen demand. It is not clear whether levosimendan can reduce mortality in cardiac surgery patients with LVD. The PubMed, Embase, and Cochrane Central databases were searched to identify randomized trials comparing levosimendan with conventional treatment in cardiac surgery patients with LVD. We derived pooled risk ratios (RRs) with random efects models. The primary endpoint was perioperative mortality. Secondary endpoints were renal replacement treatment, atrial fbrillation, myocardial infarction, ventricular arrhythmia, and hypotension. Fifteen studies enrolling 2606 patients were included. Levosimendan reduced the incidence of perioperative mortality (RR: 0.64, 95%CI: 0.45–0.91) and renal replacement treatment (RR:0.71, 95%CI:0.52–0.95). However, sensitivity analysis, subgroup analysis and Trial Sequential Analysis (TSA) indicated that more evidence was needed. Furthermore, levosimendan did not reduce the incidence of atrial fbrillation (RR:0.82, 95%CI:0.64–1.07), myocardial infarction (RR:0.56, 95%CI:0.26–1.23), or ventricular arrhythmia (RR:0.74, 95%CI:0.49–1.11), but it increased the incidence of hypotension (RR:1.11,95%CI:1.00–1.23). There was not enough high-quality evidence to either support or contraindicate the use of levosimendan in cardiac surgery patients with LVD.
    [Show full text]